echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Giniteni is listed as a clinically in urgent need of new drugs from abroad

    Giniteni is listed as a clinically in urgent need of new drugs from abroad

    • Last Update: 2021-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medicine Network November 24 - Acute myeloid leukemia (AML) is a tumor that affects blood and bone marrow, and its incidence increases with age.
    AML is one of the most common types of leukemia in adults.
    Reporters learned on the 24th, for the treatment of adult patients with FLT3 mutation relapsed or refractory acute myeloid leukemia fumaric acid ginni tablets (collectively referred to as gilitinib) was included in the Third Batch of China's State Drug Administration Drug Review Center (CDE) clinically in urgent need of foreign new drugs list.
    understand that the innovative drug's new drug licensing application has been included in the priority review.
    about 80,000 people in China are diagnosed with leukemia each year.
    In the past ten years, the treatment of recurring incurable acute myeloid leukemia has been slow, with short survival and many complications, except for resurrive chemotherapy and hematopoietic stem cell transplantation.
    it is understood that the emergence of gininib will break through the status quo of drug-free.
    , it is understood that prior to the United States, Japan, the European Union, some countries and regions to bring the gospel to patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.